After a record year for biotech IPOs in 2020, forecasts were bullish on another strong year showing for public offerings — and 2021 hasn’t disappointed so far. Now, a clutch of four biotechs chasing rare disease and cancer and a New York SPAC are ready to join the party. Three more companies filed to head […]
We take a look at some of the COVID-19 vaccine candidates moving through Phase 1 and 2 clinical trials – and how they could offer a point of difference to authorized vaccines. While vaccines from big names such as Pfizer/BioNTech, Moderna and AstraZeneca are rolling out across the world, there are currently 64 vaccines in […]
Dr. Caroline Loew, President and CEO of Glympse Bio, a clinical stage biotechnology company, discusses the company’s development of tunable biosensors capable of noninvasive disease monitoring in NASH, other fibrotic diseases, and Non-Small Cell Lung Cancer. They serve as a repeatable alternative to biopsy, allowing patients to be monitored more frequently without the need for […]